Back To Search Instructions
Protocols
196 protocols meet the specified criteria
Protocol No.TitleStatus
0100000331ANBL00B1: Neuroblastoma Biology StudiesOpen
0200000785Core: A Tissue Resource (SPORE in GI Cancer)Open
0300000620Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries (1991-0002)Open
0500000013D9902: A COG Soft Tissue Biology and Banking ProtocolOpen
0500000226Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
0600000456AREN03B2: Renal Tumors Classification, Biology and Banking StudyOpen
0600000477DATABASE FOR INDIVIDUALS AT HIGH RISK FOR BREAST, OVARIAN AND OTHER HEREDITARY CANCERSOpen
0600000609Arizona Cancer Center Biospecimen RepositoryOpen
0800001145AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research SpecimensOpen
0900000967Lymphoma Outcomes and Epidemiological DatabaseOpen
1000000254GOG 0249 - A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma Closed
1000000475GOG 0252 A Phase III Clinical Trial of Bevacizumag with IV versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #7921)Closed
1000000637COG AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)Open
1000000857GOG0262_ A RANDOMIZED PHASE III TRIAL OF EVERY-3-WEEKS PACLITAXEL VERSUS DOSE DENSE WEEKLY PACLITAXEL IN COMBINATION WITH CARBOPLATIN WITH OR WITHOUT CONCURRENT AND CONSOLIDATION BEVACIZUMAB (NSC #704865, IND #7921) IN THE TREATMENT OF PRIMARY STAGE III OR IV EPITHELIAL OVARIAN, PERITONEAL OR FALLOPIAN TUBE CANCERClosed
1100000212Skin Cancer Institute Patient Registry and Tissue BankOpen
1100000610A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications (10-CBA)Open
1200000138Biospecimen Repository for Individuals at High Risk for Breast, Ovarian, or Other Hereditary CancersOpen
1200000177COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive MutationsOpen
1200000229Skin Cancer Prevention Program BiorepositoryOpen
1200000320Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG-0273)Closed
1200000556Can diet and physical activity modulate ovarian, fallopian tube and primary peritoneal cancer progression-free survival? (GOG-0225) (LIVES)Open
1300000027S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapyOpen
1300000043Effects of Heavy Metal Exposure on DNA RepairOpen
1300000153Investigating DNA repair mechanisms, hypoxia and hypoxia signaling pathway markers in breast cancer patientsOpen
1300000173Research Retention Strategies for Cancer Survivorship Studies: A Survey of Participant OpinionsOpen
1300000431N1048(PROSPECT**): A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision ** Pre-operative Radiation Or Selective Preoperative radiation and Evaluation before Chemotherapy and TMEOpen
1300000688A retrospective review of patients receiving concurrent capecitabine and radiation therapy for high risk breast cancerOpen
1300000755A Randomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (Herceptin) in HER2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma (Yale-USPC) Phase 2 / Carbo+taxel +/- Trastuzumab / HER2/neu+, Uterine Serous Papillary Carcinoma (Yale-USPC) Closed
1403248464Alliance A011106 ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III StudyOpen
1403269898Clinical study of the effect of combined treatment of aspirin and zileuton on biomarkers of tobacco-related carcinogenesis in current smokers Open
1404299159Imaging of the ovary with a volume holographic imaging system: pilot studyOpen
1405319847My Life Our Future: A Hemophilia Genotyping Initiative Data and Sample Research RepositoryOpen
1406354010Continuation of a previously approved retrospective review, and a proposal to open a Propsective Registry for patients treated with the Xoft Axxent System device to track safety, efficacy, and cosmetic outcomes in patients with basal and squamous cell cancers.Open
1408448583The Use of In Vivo Confocal Microscopy In Normal and Pathological Cutaneous Lesions Open
1409505107Pilot Study to Evaluate the Signaling Pathway Modulation Demonstrated by Raf, MEK, and Kinase Inhibitors In Human Skin With or Without Solar Simulated LightOpen
1410547210Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active SurveillanceOpen (affiliates only)
1411572748A Novel Method of Screening for Ovarian Cancer using Gynecologic Fluids and Mucus (USA-MCI GON-1.04)Closed
1412595351A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NCS#91485) Verses Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stave IVB, or Recurrent Enometrial Cancer (GOG286b)Closed
1501622398COG ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus PazopanibOpen
1501629128AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B Lymphoblastic Leukemia (B-ALL)Open
1504771536Continued Recruitment of High-Risk and Low-Risk control subjects to assess biomarkers of ovarian cancer riskOpen
1504814936AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing SarcomaOpen
1504815014ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk NeuroblastomaOpen
1504815306AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and AdolescentsOpen
1505838152A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerClosed
1505875499Precision Medicine & Genomic Analyses Protocol for OncologyOpen
1505889122A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in AdultsOpen
1508065953Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (A151216) (A Screening Trial for A081105 and E4512)Open
1509106328ALTE11C2: Health Effects after Anthracycline and Radiation Therapy: Dexrazoxane and Prevention of Anthracycline-related CardiomyopathyOpen
1509119432E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinOpen
1509136789ALTE05N1: Umbrella Long-Term Follow-Up ProtocolOpen
1509137444Randomized Double Blind Placebo Controlled Study of Erlotinib orObservation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR)Mutant Non-Small Cell Lung Cancer (NSCLC) (ALCHEMIST) (A081105)Open
1512277664APEC14B1: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome StudyOpen
1602381312A PHASE 1A/B STUDY OF THE FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORSNot Open
1602386062A Phase Ib/II Study Evaluating The Safety And Efficacy Of Obinutuzumab In Combination With Polatuzumab Vedotin And Venetoclax In Patients With Relapsed Or Refractory Follicular Lymphoma And Rituximab In Combination With Polatuzumab Vedotin And Venetoclax In Patients With Relapsed Or Refractory Diffuse Large B-Cell LymphomaOpen
1603445994U1EMC27862: Pacific Sickle Cell Regional Collaborative Minimum Data SetOpen
1603472947Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaOpen
1604498313Preclinical Investigation of Novel Therapeutic Agents for Hematological Malignancies Open
1604536433A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
1605600303Isolation and Characterization of Circulating Tumor Cells (CTCs)Open
1606616633Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)Open
1606619215An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerOpen
1606636273A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal CancerOpen
1606636756ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide Alternating with Vincristine and Irinotecan Versus VAC/VI Plus Temsirolimus in Patients with Intermediate Risk RhabdomyosarcomaOpen
1606665114A091304: A Phase I/ II Randomized Phase II Study of MLN0128 Vs. Pazopanib in Patients with Locally Advanced/ Unresectable and/or Metastatic SarcomaOpen
1607716638A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid LeukemiaOpen
1607720505EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung CancersOpen
1607724485CYTOLOGICAL CHANGES AND MOLECULAR MECHANISM UNDERLYING THE ROLE OF FALLOPIAN TUBE EPITHELIUM IN THE DEVELOPMENT OF GYNECOLOGIC MALIGNANCYOpen
1609876907A Phase I/II Study of Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide and/or BendamustineOpen
1610905065A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell TransplantOpen
1610912545INCB 54828-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous TherapyOpen
1610935809A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyOpen
1612032762A Phase 0 Study Evaluating the Systemic Bioavailability and Pharmacodynamic Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck CancerOpen
1612040295Improving Transitions of Care for HSCT Recipients After DischargeOpen
1612049078A Phase I Multicenter, Open Label Study of Enadenotucirev Combined with PD-1 Inhibitor in Subjects with Metastatic or Advanced Epithelial TumorsOpen
1612074879An Open-Label, Multicenter, Dose Escalation, Phase IA/IB Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Alpha (FAP), as a Single Agent (Part A) or in Combination with Trastuzumab or Cetuximab (Part B or C)Open
1612076335A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States (TRUMPET Registry)Open
1612084235A Phase 3 Open-Label, Randomized, Multicenter Study Of Nktr-102 Versus Treatment Of Physician¿s Choice (Tpc) In Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases And Have Been Previously Treated With An Anthracycline, A Taxane, And CapecitabineOpen
1701114637Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease RegistryOpen
1701157446METIS: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)Open
1701158847A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma To evaluate the efficacy with respect to progression-free survival (PFS) of MK-3475 administered intravenously in combination with oral dabrafenib and trametinib in subjects with advanced (unresectable or metastatic) melanoma with BRAF V600 E or K mutations, compared with placebo administered intravenously in combination with oral dabrafenib and trametinib alone. Open
1702219140Bayer 17777: A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancerOpen
1702222208A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-FailureOpen
1702240492A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerClosed
1702242206A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced MalignanciesOpen
1702242313A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell SubtypeOpen
1703269356S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.Open
1703270664A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic MelanomaOpen
1703273775EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)Open
1703305188A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)Open
1703306023A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing RegimenOpen
1704345989Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma with Molecular Correlates Open
1704383758A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular MelanomaOpen
1704390293A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsOpen
1704399751CA209651: An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)Open
1704406984A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)Open
1705411350A Randomized Phase III Trial Of TRC105 And Pazopanib Versus Pazopanib Alone In Patients With Advanced Angiosarcoma (Tappas) Open
1705427831A prospective, randomized, blinded, placebocontrolled, phase IIb trial of an autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC in stage III and stage IV (resected) melanoma to prevent recurrenceOpen
1705461569Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)Open
1705469245A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic CancersOpen
1706515486Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover StudyOpen
1706540415Real-Time Optical Biopsy for Improved Lung Cancer DiagnosisOpen
1706546860A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic DiseaseOpen
1706564897An observational study of patients with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia in the USOpen
1706595817A Multicenter, Two Part Open-Label, Phase 1b Clinical Study of CMP-001 Administered Either in Combination with Pembrolizumab or as Monotherapy in Subjects with Advanced MelanomaOpen
1707616299A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without SurgeryOpen
1707620366A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic MelanomaOpen
1707630812Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving Cytoreductive TherapyOpen
1707634514Evaluating the role of diffusion tensor imaging in predicting development of chemotherapy induced peripheral neuropathy in patients with breast cancerOpen
1707651600Retrospective review of efficacy and side effects of Daratumumab treatment in patients with Relapsed/Refractory Multiple MyelomaOpen
1707660879A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)Open
1707664489A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination with Abraxane® in Subjects with Metastatic Pancreatic CancerOpen
1707678555A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV MelanomaOpen
1707685280Retrospective Review Evaluating the Incidence of Febrile Neutropenia for Same Day versus Next Day Pegfilgrastim in Lymphoma PatientsOpen
1708698450A Phase 1b Study of Intratumoral IMO-2125 in Patients with Refractory Solid Tumors (Illuminate-101)Open
1708704370GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host DiseaseOpen
1708714400A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects with Advanced or Metastatic Solid Tumors (Stage 1 and Stage 2 of Phase 2)Open
1708719126Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient RegistryOpen
1708725986A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH 3)Open
1708730759A PHASE II EVALUATION OF COPANLISIB (BAY 80-6946) (IND #130822), A SELECTIVE INHIBITOR OF PI3KCA, IN PATIENTS WITH PERSISTENT OR RECURRENT ENDOMETRIAL CARCINOMA HARBORING PIK3CA HOTSPOT MUTATIONSNot Open
1709802216Retrospective Review: Targeting hyperactive DNA break repair in glioblastomaOpen
1709807187A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid LeukemiaOpen
1709836270Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast CancerOpen
1709857266A retrospective review of prevention of fungal infections using fluconazole as prophylaxis in the adult and pediatric allogeneic stem cell transplant populationOpen
1709868869Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid TumorsOpen
1709869722A PHASE III, OPEN-LABEL, MULTICENTER,TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMAOpen
1710879810A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination with Cetuximab in Patients with Advanced Head and Neck Squamous Cell CarcinomaOpen
1710900482A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell LymphomaOpen
1710900606Qualitative Study to Understand the Emotional Response to a Metastatic Diagnosis in Castration-Resistant Prostate CancerOpen
1710917371S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular LymphomaNot Open
1710919668MonarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, BreastCancerOpen
1710965268A Randomized, Phase II Study of Ficlatuzumab with or without Cetuximab in Patients with Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaOpen
1711012625Safety and Efficacy of Filgrastim-sndz in Combination with Plerixafor followed by Post autologous stem cell infusion for Autologous peripheral blood stem cell transplantation Open
1711015269A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate Safety and Efficacy of Avelumab (MSB0010718C) in Combination with Chemotherapy with or without Other Anti-Cancer Immunotherapies as First-Line Treatment in Patients with Advanced MalignanciesOpen
1711022046Clinical Study of Avmacol® for Detoxification of Tobacco Carcinogens in Heavy SmokersOpen
1711034234Dose Adjustment and Compliance of Immunomodulatory Drugs in Multiple Myeloma Patients at Arizona Cancer CenterOpen
1711993144A Prospective Quality of Life Study in Metastatic Pancreatic CancerOpen
1711993805An Open-Label, Single Sequence, Crossover Drug-Drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in PatientsOpen
1712078374Pilot Trial to Evaluate Blood and Imaging Based Biomarkers for Aromatase Inhibitor Induced Musculoskeletal Syndrome Open
1712087417FIGHT: A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal CancerOpen
1712110914Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell LymphomaNot Open
1712133119A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's LymphomaOpen
1801172278Evaluation of Clinical Outcomes in the Utilization of Next Generation Sequencing for Metastatic Colorectal Cancer PatientsOpen
1802236187A Phase 3, Open-Label, Randomized, Multicenter, Controlled Trial To Evaluate The Pharmacokinetics And Pharmacodynamics Of Edoxaban And To Compare The Efficacy And Safety Of Edoxaban With Standard Of Care Anticoagulant Therapy In Pediatric Subjects From Birth To Less Than 18 Years Of Age With Confirmed Venous Thromboembolism (VTE)Open
1802249145A Randomized, Double-Blind, Placebo Controlled, Phase 3 study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)Open
1802269227A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid TumorsOpen
1802319251NRG HN-004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin.Open
1803362975I5B-MC-JGDP(c) A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer Not Open
2002-0063Protocol for a Research Database For Hematopoieitc Stem Cell Transplantation and Marrow Toxic InjuriesOpen
25207Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients Open
27547A Phase 1/2 Study of INCB053914 in Subjects With Advanced MalignanciesNot Open
28508A prospective, multicentre, randomised, controlled study evaluating SIR-Spheres® Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM) chemotherapy versus CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic CholangioCArcinoma (SIRCCA)Not Open
28607A Phase I/II study of Syk inhibitor entospletinib (GS-9973) in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell malignanciesNot Open
28807A RANDOMIZED PHASE II STUDY OF TRASTUZUMAB AND PERTUZUMAB (TP) COMPARED TO CETUXIMAB AND IRINOTECAN (CETIRI) IN ADVANCED/METASTATIC COLORECTAL CANCER (MCRC) WITH HER-2 AMPLIFICATIONNot Open
28808Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal CancerNot Open
29027A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian CancerNot Open
PHX28467Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma in Basal Cell Nevus SyndromeNot Open
PHXA-15-0002-10-15Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?Open
PHXA-15-0003-10-15GROningen INternational Study on Sentinel nodes in Vulvar cancer GROINSS-V) Closed
PHXA-15-0012-10-15RANDOMIZED PHASE II/III TRIAL OF SURGERY AND POSTOPERATIVE RADIATION DELIVERED WITH CONCURRENT CISPLATIN VERSUS DOCETAXEL VERSUS DOCETAXEL AND CETUXIMAB FOR HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECKNot Open
PHXA-15-0013-10-15S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy Open
PHXA-15-0028-80-15A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerClosed
PHXA-16-0003-80-15A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell CarcinomaClosed
PHXA-16-0064-80-15A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi Center, Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis(OM) in Patients Receiving Post-Operative or Definitive Therapy with Single-Agent Cisplatin plus IMRT for Locally Advanced, Non-Metastatic Squamous Cell Carcinoma of the Oral Cavity or OropharynxClosed
PHXA-16-0094-80-15PHASE 3 STUDY OF ADXS11-001 ADMINISTERED FOLLOWING CHEMORADIATION AS ADJUVANT TREATMENT FOR HIGH RISK LOCALLY ADVANCED CERVICAL CANCER:AIM2CERV Open
PHXA-16-0174-80-15A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian CancerOpen
PHXA-16-0212-80-15Androgen Deprivation Therapy with or without Radium-223 dichloride in Patients with Newly Diagnosed Metastatic Prostate Cancer with Bone MetastasesNot Open
PHXA-17-0030-71-15A retrospective study on the outcome of patients with genitourinary (GU) malignancies who were treated at Dignity Health St. Joseph's Hospital and Medical Center (including University of Arizona Cancer Center at Dignity Health St. Joseph's)Open
PHXA-17-0242-71-15Aerobic Interval Exercise Preconditioning to Prevent Cardiometabolic and Neuropsychological Complications of Anthracycline Based Breast Cancer ChemotherapyOpen
PHXB-11OB053Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical HysterectomyClosed
PHXB-11OB103A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL (ANZGOG 0902)Closed
PHXB-13RT127Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma Open
PHXB-15-0004-10-15Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lympadenectomy) for Stage 1A1 (LVSI+) and IA2-IB1 (¡Ü 2CM) Cervical CancerClosed
PHXB-15-0011-80-15SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerOpen
PHXB-15-0014-10-15A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder CancerClosed
PHXB-15-0015-80-15A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States Open
PHXB-15-0018-10-15Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic LymphadenectomyClosed
PHXB-16-0026-71-16Brachytherapy for Treatment of Esophageal MalignanciesOpen
PHXB-16-0142-80-15Cyclic PDT for the Prevention of Actinic Keratosis and Non Melanoma Skin Cancer in Solid Organ Transplant RecipientsOpen
PHXB-17-0013-71-16Dosimetric comparison for IMRT, VMAT, SBRT/SRS, & Brachytherapy for extracranial sitesOpen
PHXB-17-0072-70-15Clinical evaluation of everolimus (a rapamycin analog) in restoring salivary gland function to patients treated with radiotherapy for head and neck cancerOpen
PHXE-15-0038-10-15A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate CancerNot Open
PHXE-16-0167-10-15A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant ChemotherapyOpen
PHXE-16-0179-80-15A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ká Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial CancerOpen
PHXE-16-0204-80-15A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer Open
PHXE-16-0213-80-15A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCEROpen
PHXE-17-0101-80-15A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor TherapyOpen
PHXE-17-0114-10-15A Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) Open
PHXE-17-0117-80-15A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell LymphomaOpen
PHXE-17-0216-10-15EAY131: Molecular Analysis for Therapy Choice (MATCH) Open
PHXE-17-0349-10-15DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsOpen
PHXE-17-0351-10-15A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery.Open
PHXE-17-0356-80-15MonarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, BreastCancerOpen
PHXE-17-0373-10-15A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (CT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPYNot Open
PHXE-17-0374-10-15RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCERNot Open
TESTCALENDAROpen